References
1. Femia A, Vleugels RA. Pediatric Autoimmune Connective Tissue
Diseases: An Update on Disease Characteristics, Associations, and
Management. Curr Derm Rep Current Dermatology Reports.2013;2(4):216-229.
2. Grein IHR, Pelajo CF, Meneghetti TC, Junior LLJ, Bandeira M.
Pulmonary Manifestations of Rheumatologic Diseases in Pediatric.Rheumatol Curr Res Rheumatology: Current Research. 2014;04(02).
3. Reed A. Dermatomyositis (Juvenile). 2014.
4. Solomon JJ, Fischer A. Connective Tissue Disease-Associated
Interstitial Lung Disease: A Focused Review. Journal of intensive
care medicine. 2015;30(7):392-400.
5. Malattia C, Martini A. Paediatric-onset systemic lupus erythematosus.Best practice & research. Clinical rheumatology.2013;27(3):351-362.
6. Oguz EO, Kucuksahin O, Turgay M, et al. Association of serum KL-6
levels with interstitial lung disease in patients with connective tissue
disease: a cross-sectional study. Clin. Rheumatol. Clinical
Rheumatology. 2016;35(3):663-666.
7. Navallas M, Inarejos Clemente EJ, Iglesias E, Rebollo-Polo M, Antón
J, Navarro OM. Connective Tissue Disorders in Childhood: Are They All
the Same? Radiographics : a review publication of the Radiological
Society of North America, Inc. 2019;39(1).
8. Saper VE, Chen G, Deutsch GH, et al. Emergent high fatality lung
disease in systemic juvenile arthritis. Annals of the rheumatic
diseases. 2019;78(12):1722-1732.
9. Griese M, Haug M, Brasch F, et al. Incidence and classification of
pediatric diffuse parenchymal lung diseases in Germany. Orphanet J
Rare Dis. 2009;4:26.
10. Kornum JB, Christensen S, Grijota M, et al. The incidence of
interstitial lung disease 1995-2005: a Danish nationwide
population-based study. BMC Pulm Med. 2008;8:24.
11. Dinwiddie R, Sharief N, Crawford O. Idiopathic interstitial
pneumonitis in children: a national survey in the United Kingdom and
Ireland. Pediatr Pulmonol. 2002;34(1):23-29.
12. Fischer A, Chartrand S. Assessment and management of connective
tissue disease-associated interstitial lung disease. Sarcoidosis
Vasc Diffuse Lung Dis. 2015; 22(32):2–21.
13. Satoh H, Kurishima K, Ishikawa H, Ohtsuka M. Increased levels of
KL-6 and subsequent mortality in patients with interstitial lung
diseases. JOIM Journal of Internal Medicine. 2006;260(5):429-434.
14. Mikolasch TA, Garthwaite HS, Porter JC. Update in diagnosis and
management of interstitial lung disease. Clin Med Clinical
Medicine. 2016;16(Suppl 6):s71-s78.
15. Olson AL, Brown KK, Fischer A. Connective tissue disease-associated
lung disease. Immunology and allergy clinics of North America.2012;32(4):513-536.
16. Atzeni F, Boiardi L, Sallì S, Benucci M, Sarzi-Puttini P. Lung
involvement and drug-induced lung disease in patients with rheumatoid
arthritis. Expert review of clinical immunology.2013;9(7):649-657.
17. Assayag D, Lee J, King T. Rheumatoid arthritis associated
interstitial lung
disease: a review. Medicina (B Aires). 2014;74:158–165.
18. Shaw M, Collins BF, Ho LA, Raghu G. Rheumatoid arthritis-associated
lung disease. Eur Respir Rev European respiratory review : an
official journal of the European Respiratory Society.2015;24(135):1-16.
19. Wynn T. Integrating mechanisms of pulmonary fibrosis. J Exp
Med. 2011;208:1339–1350.
20. Jiang Z, Tao JH, Zuo T, et al. The correlation between miR-200c and
the severity of interstitial lung disease associated with different
connective tissue diseases. Scandinavian Journal of Rheumatology
Scandinavian Journal of Rheumatology. 2017;46(2):122-129.
21. Hu Y, Wang L-S, Jin Y-P, et al. Serum Krebs von den Lungen-6 level
as a diagnostic biomarker for interstitial lung disease in Chinese
patients KL-6 for ILDs in Chinese patients. The Clinical
Respiratory Journal The Clinical Respiratory Journal.2015;11(3):337-345.
22. Ishikawa N, Hattori N, Kohno N, Yokoyama A. Utility of KL-6/MUC1 in
the clinical management of interstitial lung diseases. Respir.
Invest. Respiratory Investigation. 2012;50(1):3-13.
23. Sato S, Hoshino K, Satoh T, et al. RNA helicase encoded by melanoma
differentiation-associated gene 5 is a major autoantigen in patients
with clinically amyopathic dermatomyositis: Association with rapidly
progressive interstitial lung disease. Arthritis Rheum. Arthritis
and Rheumatism. 2009;60(7):2193-2200.
24. Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid Arthritis
Classification Criteria An American College of Rheumatology/European
League Against Rheumatism Collaborative Initiative. Arthritis and
rheumatism. 2010;62(9):2569-2581.
25. Aringer M, Costenbader K, Daikh D, et al. 2019 European League
Against Rheumatism/American College of Rheumatology classification
criteria for systemic lupus erythematosus. Annals of the rheumatic
diseases. 2019;78(9):1151-1159.
26. Lundberg IE, Tjärnlund A, Bottai M, et al. 2017 European League
Against Rheumatism/American College of Rheumatology classification
criteria for adult and juvenile idiopathic inflammatory myopathies and
their major subgroups. Annals of the rheumatic diseases.2017;76(12):1955-1964.
27. Zulian F, Woo P, Athreya BH, et al. The Pediatric Rheumatology
European Society/American College of Rheumatology/European League
against Rheumatism provisional classification criteria for juvenile
systemic sclerosis. ART Arthritis Care & Research.2007;57(2):203-212.
28. Tanaka Y, Kuwana M, Fujii T, et al. 2019 Diagnostic criteria for
mixed connective tissue disease (MCTD): From the Japan research
committee of the ministry of health, labor, and welfare for systemic
autoimmune diseases. Modern Rheumatology. 2020:1-5.
29. Popler J, Lesnick B, Dishop MK, Deterding RR. New Coding in the
International Classification of Diseases, Ninth Revision, for Children’s
Interstitial Lung Disease. CHEST Chest. 2012;142(3):774-780.
30. Kurland G, Deterding RR, Hagood JS, et al. An official American
Thoracic Society clinical practice guideline: classification,
evaluation, and management of childhood interstitial lung disease in
infancy. American journal of respiratory and critical care
medicine. 2013;188(3):376-394.
31. Kuo CS, Young LR. Interstitial lung disease in children.Current opinion in pediatrics. 2014;26(3):320-327.
32. Bush A, Cunningham S, de Blic J, et al. European protocols for the
diagnosis and initial treatment of interstitial lung disease in
children. Thorax. 2015;70(11):1078-1084.
33. Shapiro DE. The interpretation of diagnostic tests.Statistical Methods in Medical Research. 1999;8(2):113-134.
34. Benyamine A, Heim X, Resseguier N, et al. Elevated serum Krebs von
den Lungen-6 in systemic sclerosis: a marker of lung fibrosis and
severity of the disease. Rheumatol Int Rheumatology International
: Clinical and Experimental Investigations. 2018;38(5):813-819.
35. Satoh H, Kurishima K, Ishikawa H, Ohtsuka M. Increased levels of
KL-6 and subsequent mortality in patients with interstitial lung
diseases. J Intern Med Journal of Internal Medicine.2006;260(5):429-434.
36. Kumanovics G, Gorbe E, Minier T, Simon D, Berki T, Czirjak L.
Follow-up of serum KL-6 lung fibrosis biomarker levels in 173 patients
with systemic sclerosis. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY.2014;32(6):S138-S144.
37. Salazar GA, Kuwana M, Wu M, et al. KL-6 But Not CCL-18 Is a
Predictor of Early Progression in Systemic Sclerosis-related
Interstitial Lung Disease. The Journal of rheumatology.2018;45(8):1153-1158.
38. Hu C, Wu C, Yang E, et al. Serum KL-6 is associated with the
severity of interstitial lung disease in Chinese patients with
polymyositis and dermatomyositis. Clinical Rheumatology.2019;38(8):2181-2187.
39. Hanaoka M, Katsumata Y, Kawasumi H, Kawaguchi Y, Yamanaka H. KL-6 is
a long-term disease-activity biomarker for interstitial lung disease
associated with polymyositis/dermatomyositis, but is not a short-term
disease-activity biomarker. Modern rheumatology.2019;29(4):625-632.
40. Hu Y, Wang L-S, Jin Y-P, et al. Serum Krebs von den Lungen-6 level
as a diagnostic biomarker for interstitial lung disease in Chinese
patients KL-6 for ILDs in Chinese patients. The Clinical
Respiratory Journal The Clinical Respiratory Journal.2017;11(3):337-345.
41. Kilinc AA, Arslan A, Yildiz M, et al. Serum KL-6 level as a
biomarker of interstitial lung disease in childhood connective tissue
diseases: a pilot study. Rheumatology international. 2019.
42. Fathi M, Barbasso Helmers S, Lundberg IE. KL-6: a serological
biomarker for interstitial lung disease in patients with polymyositis
and dermatomyositis KL-6: a serological biomarker for interstitial lung
disease. Journal of Internal Medicine. 2012;271(6):589-597.
43. Fukaya S, Oshima H, Kato K, et al. KL-6 as a novel marker for
activities of interstitial pneumonia in connective tissue diseases.Rheumatology international. 2000;19(6):223.
44. Kinoshita F, Hamano H, Harada H, et al. Role of KL-6 in evaluating
the disease severity of rheumatoid lung disease: comparison with HRCT.Respiratory medicine. 2004;98(11):1131-1137.
45. Bonella F, Volpe A, Caramaschi P, et al. Surfactant protein D and
KL-6 serum levels in systemic sclerosis: correlation with lung and
systemic involvement. Sarcoidosis Vasc Diffuse Lung Dis.2011;28(1):27-33.
46. Yamakawa H, Hagiwara E, Kitamura H, et al. Serum KL-6 and surfactant
protein-D as monitoring and predictive markers of interstitial lung
disease in patients with systemic sclerosis and mixed connective tissue
disease. Journal of thoracic disease. 2017;9(2):362-371.
47. Cao X-Y, Hu S-S, Xu D, et al. Serum levels of Krebs von den Lungen-6
as a promising marker for predicting occurrence and deterioration of
systemic sclerosis-associated interstitial lung disease from a Chinese
cohort. Int J Rheum Dis. 2019;22(1):108-115.